TY - JOUR T1 - The equivalence of hydration status measured by the Fresenius BCM and the Cella Bioimpedance Spectroscopy devices on hemodialysis patients JF - medRxiv DO - 10.1101/2021.09.13.21263290 SP - 2021.09.13.21263290 AU - Jim Matthie AU - Borut Baricevic AU - Vlasta Malnaric Marentic AU - Boris Krajacic Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/17/2021.09.13.21263290.abstract N2 - Background Fluid management is a serious challenge for patients undergoing hemodialysis therapy (HD). Bioimpedance spectroscopy (BIS) is a promising technique to help with clinical hydration (HYD) assessment. The Fresenius Medical Care (FMC) Body Composition Monitor (BCM) is the standard but is large and expensive. Cella Medical has introduced a small wireless BIS device. This study compared the HYD status predicted by the two devices.Methods Following the FMC BCM device manual guidelines, measurements of BIS were made wrist-ankle using typical ECG electrodes on the non-fistula side of HD patients pre dialysis while in their normal supine position. As usual, patients were measured before their normal time of therapy with the BCM. The Cella measurements were then performed within two minutes.Results Forty-two HD patients (M=64%, age=64±30 yrs.), were measured. One patient data was removed. The mean BCM HYD status was 1.86 l, SD 1.46 l, and SEM 0.22 l. Cella was 1.806 l, SD 1.36 l, and the SEM 0.21 l. The 95% difference confidence interval (CI) was -0.66 to 0.55 l. The Pearson’s correlation (r) was r^2 = 0.85 (p<0.00001). There was no proportional bias: the offset was -0.056 l, and K=1.010. The limits of agreement (LOA) analysis showed a mean difference of 0.56 l, and limits d ±2SD = (−1.192 l, 1.081 l), indicating 95% of the difference will lie within these limits. To evaluate equivalence, we performed two one-sided t-tests (TOST). When the bounds were reduced to the limit =0.47 l and -0.59 l, we obtained a 0.046 p-value (alpha =0.05), at 80% statistical power. For 26% of the subjects, the difference was <0.1 l, for 43% <0.25 l, for 71% <0.5 l, for 83% <0.75 l, for 90% <1.0 l, and for 9.5% (4 patients) more than 1 l. Only two cases (4.8%) were just over the ±2SD limit.Conclusion This study suggests the BCM and Cella devices can be used interchangeably.Competing Interest StatementJM co-founded Xitron Technologies, Inc., co-developed their medical BIS device and licensed it to FMC, where it became the basis of the BCM. He no longer benefits financially. Matthie is co-founder of Cella Medical, Inc., co-developed their Cella device and has economic interest. BB co-founded Cella Medical, Inc., is Chief Technology Officer, co-developed their Cella device, and has economic interest. VMM has no conflicts to disclose. BK is a consultant to Cella Medical, Inc. and has economic interest. Clinical TrialThis is a non-interventional clinical studyFunding StatementThe study described herein was sponsored by Cella Medical, Inc., a corporation with an office at 4250 Executive Square, Ste. 675, La Jolla, CA 92037. This includes CELLA medical devices and consumable materials. Authors were not paid for their work but (1, 2, 4) hold economic interest in Cella Medical, Inc., while author 3 does not. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Slovenian National Ethics Commission approval for the study (doc number: 0120-493/2019/15)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAs a non-interventional study, no data beyond what this paper reports are available. Replication of this study's results requires FMC BCM and CELLA BIS devices. Contact Cella Medical and Fresenius Medical Care for device availability. ER -